Why the study?
Does chronic neutral endopeptidase inhibition improve hemodynamic and renal function compared to furosemide in an ovine model of heart failure?
Does chronic neutral endopeptidase inhibition improve hemodynamic and renal function compared to furosemide in an ovine model of heart failure?
In an ovine model of heart failure, chronic neutral endopeptidase inhibition is as effective as furosemide in reducing cardiac preload and altering renal function.
Animal data support testing chronic NEP inhibition for preload reduction in HF; human trials needed before any clinical role.
The hemodynamic, hormonal, and metabolic effects of chronic neutral endopeptidase (NEP) 24.11 inhibition and furosemide were compared in the pacing model of ovine heart failure (HF). Intravenous SCH 39370 induced a dose-related inhibition of NEP activity during 4-days treatment, in association with a transient increase in plasma atrial natriuretic peptide (ANP) and, at the higher dose, an increased mean level of plasma cyclic guanosine monophosphate. There was a significant and persistent decrease in left atrial pressure, a brief increase in cardiac output (CO), and a tendency for arterial pressure to be reduced. Significant dose-related diuresis and natriuresis were also observed. Furosemide induced a similar hemodynamic response, associated with greater diuresis and natriuresis. Both agents significantly reduced plasma aldosterone levels. Coinfusion of captopril on day 4 of treatment resulted in similar responses in both the SCH 39370- and furosemide pretreated groups. Chronic NEP inhibition significantly alters circulatory and renal function and appears to be as effective as furosemide in reducing cardiac preload in this model of congestive HF.
No takes yet. Share an insight, caveat, or question.
Rademaker et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: